Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: homologymedicines.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2023 | $9.00 → $1.50 | Outperform → Neutral | Robert W. Baird |
| 2/28/2022 | $30.00 → $20.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $25.00 → $9.00 | Buy | B of A Securities |
| 2/22/2022 | $35.00 → $29.00 | Neutral | BTIG Research |
| 2/22/2022 | Outperform → Sector Perform | RBC Capital Mkts | |
| 2/22/2022 | $25.00 → $15.00 | Buy | Chardan Capital |
| 2/22/2022 | $35.00 → $29.00 | Buy | BTIG |
| 2/22/2022 | $30.00 → $4.00 | Outperform → Sector Perform | RBC Capital |
| 2/22/2022 | Outperform → Perform | Oppenheimer | |
| 11/16/2021 | $30.00 → $25.00 | Buy | Chardan Capital |
- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named Pr
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicines platform Oxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer status Dr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board Director of Oxford Biomedica Oxford Biomedica and Homology Medicines to host webcasts t
SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)
SC 13D - Q32 Bio Inc. (0001661998) (Subject)
SC 13D - Q32 Bio Inc. (0001661998) (Subject)
SC 13G - Q32 Bio Inc. (0001661998) (Subject)
SC 13D - Q32 Bio Inc. (0001661998) (Subject)
SC 13G - Homology Medicines, Inc. (0001661998) (Subject)
SC 13G/A - Homology Medicines, Inc. (0001661998) (Subject)
SC 13G/A - Homology Medicines, Inc. (0001661998) (Subject)
SC 13G/A - Homology Medicines, Inc. (0001661998) (Subject)
SC 13G/A - Homology Medicines, Inc. (0001661998) (Subject)
424B3 - Q32 Bio Inc. (0001661998) (Filer)
10-Q - Q32 Bio Inc. (0001661998) (Filer)
8-K - Q32 Bio Inc. (0001661998) (Filer)
EFFECT - Q32 Bio Inc. (0001661998) (Filer)
424B3 - Q32 Bio Inc. (0001661998) (Filer)
S-1 - Q32 Bio Inc. (0001661998) (Filer)
10-K/A - Q32 Bio Inc. (0001661998) (Filer)
8-K - Q32 Bio Inc. (0001661998) (Filer)
8-K/A - Homology Medicines, Inc. (0001661998) (Filer)
8-K - Homology Medicines, Inc. (0001661998) (Filer)
Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously
HC Wainwright & Co. reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $20.00 from $30.00 previously
B of A Securities reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $9.00 from $25.00 previously
BTIG Research reiterated coverage of Homology Medicines with a rating of Neutral and set a new price target of $29.00 from $35.00 previously
RBC Capital Mkts downgraded Homology Medicines from Outperform to Sector Perform
Chardan Capital reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $15.00 from $25.00 previously
BTIG reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $29.00 from $35.00 previously
RBC Capital downgraded Homology Medicines from Outperform to Sector Perform and set a new price target of $4.00 from $30.00 previously
Oppenheimer downgraded Homology Medicines from Outperform to Perform
Chardan Capital reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $25.00 from $30.00 previously
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price RequirementHomology Medicines, Inc. (NASDAQ:FIXX) today announced that it received notification ("Nasdaq Notification") from The Nasdaq Stock Market LLC ("Nasdaq") on December 29, 2023 indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market (Nasdaq Listing Rule 5450(a)(1)). The Nasdaq Notification has no immediate effect on the listing of the Common Shares on the Nasdaq Capital Market. In accordance with the N
Gainers NGM Biopharmaceuticals (NASDAQ:NGM) shares moved upwards by 43.2% to $1.23 during Monday's after-market session. The company's market cap stands at $101.7 million. Cue Health (NASDAQ:HLTH) shares rose 35.38% to $0.22. The market value of their outstanding shares is at $34.0 million. Homology Medicines (NASDAQ:FIXX) stock increased by 12.46% to $0.64. The market value of their outstanding shares is at $36.8 million. Cue Biopharma (NASDAQ:CUE) shares moved upwards by 10.05% to $2.9. The company's market cap stands at $130.8 million. Cadrenal Therapeutics (NASDAQ:CVKD) shares increased by 9.68% to $0.78. The company's market cap stands at $10.1 million. Biophytis (NASDAQ:BPTS) sha
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 100 points on Thursday. The Dow traded down 0.39% to 34,853.42 while the NASDAQ fell 0.11% to 14,087.96. The S&P 500 also fell, dropping, 0.09% to 4,498.85. Check This Out: Top 4 Financial Stocks You'll Regret Missing This Month Leading and Lagging Sectors Utilities shares surged by 1% on Thursday. In trading on Thursday, energy shares fell by 2.2%. Top Headline Williams-Sonoma, Inc. (NYSE:WSM) reported better-than-expected third-quarter adjusted earnings. Williams-Sonoma posted non-GAAP earnings of $3.66 per share, versus market estimates of $3.35 per share. The company’s quarterly
Shares of The Children's Place, Inc. (NASDAQ:PLCE) moved lower during Thursday’s session following weak quarterly earnings. Children's Place posted adjusted earnings of $3.22 per share, missing market estimates of $3.56 per share. The company’s quarterly sales came in at $480.23 million versus estimates of $471.82 million, according to Benzinga Pro. Children's Place shares tumbled 25.6% to $21.23 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers WaveDancer, Inc. (NASDAQ:WAVD) climbed 80.1% to $2.7201 after the company inked a definitive merger agreement with Firefly Neuroscience in an all-stock transaction. Apollomics, Inc. (NASDAQ:APLM) shares climb
Gainers LumiraDx (NASDAQ:LMDX) shares rose 42.8% to $0.14 during Thursday's regular session. LumiraDx's stock is trading at a volume of 62.6 million shares as of 12:30 EST. This is 685.7% of its average full-day volume over the last 100 days. The company's market cap stands at $45.0 million. Bone Biologics (NASDAQ:BBLG) stock rose 26.55% to $0.69. Bone Biologics's stock is trading at a volume of 39.5 million shares as of 12:30 EST. This is 11857.4% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 million. As per the news, the Q3 earnings report came out 2 days ago. Impel Pharmaceuticals (NASDAQ:IMPL) shares moved upwards by 25.04% to $0.35. As
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.40% to 34,850.49 while the NASDAQ fell 0.35% to 14,055.15. The S&P 500 also fell, dropping, 0.23% to 4,492.60. Check This Out: Top 4 Financial Stocks You'll Regret Missing This Month Leading and Lagging Sectors Utilities shares surged by 1% on Thursday. In trading on Thursday, energy shares fell by 2.2%. Top Headline Shares of Walmart Inc (NYSE:WMT) fell around 7% on Thursday after the company reported results for the third quarter. Walmart reported third-quarter FY24 sales growth of 5.2% year-over-year to $160.8 billion, beating the c
Q32 Bio Inc and Homology Medicines Inc (NASDAQ:FIXX) have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Q32 Bio's wholly-owned clinical development candidates for autoimmune and inflammatory diseases. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol "QTTB." Q32 Bio has agreed to a $42 million private placement in support of the merger agreement. Under the terms of the merger agreement, Homology Medicines will issue to pre-merger Q32 Bio stockholders shares of Homology
. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol "QTTB".
Gainers Heron Therapeutics (NASDAQ:HRTX) stock moved upwards by 63.0% to $0.88 during Wednesday's regular session. As of 12:31 EST, Heron Therapeutics's stock is trading at a volume of 15.8 million, which is 750.5% of its average full-day volume over the last 100 days. The company's market cap stands at $123.8 million. The company's, Q3 earnings came out yesterday. Kinnate Biopharma (NASDAQ:KNTE) shares increased by 57.32% to $2.47. The current volume of 55.3 million shares is 35889.2% of Kinnate Biopharma's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $116.3 million. As per the press release, Q3 earnings cam
Gainers Reata Pharmaceuticals (NASDAQ:RETA) shares moved upwards by 52.1% to $165.09 during Friday's regular session. As of 13:30 EST, Reata Pharmaceuticals's stock is trading at a volume of 9.0 million, which is 1155.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.1 billion. Homology Medicines (NASDAQ:FIXX) shares rose 37.22% to $1.29. As of 13:30 EST, this security is trading at a volume of 8.3 million shares, making up 5754.6% of its average full-day volume over the last 100 days. The company's market cap stands at $74.5 million. Bluejay Diagnostics (NASDAQ:BJDX) stock increased by 32.52% to $7.09. As of 13:30 EST, Bluejay
BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the "Gene Editing Corporate Panel" during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology's website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation. About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients
BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT"Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic" panel featuring Dr. Seymour on October 11 at 4:00 p.m. PT"New Business Models for Manufacturing Investment" panel featuring Arthur Tzianabos, Ph.D., Chairman of the Board of Homology, on October 12 at 3:15 p.m. PT
SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: FASEB's The Genome Engineering Conference: Cutting-Edge Research and Applications on June 29, 2022 at 5:30 p.m. WET/12:30 p.m. ET in Lisbon, Portugal Homology will deliver an oral presentation titled, "Molecular Characterization of In Vivo Editing in Human Hepatocytes and a PKU Mouse Model using rAAVHSCs," which confirms the precision of homologous recombination-based integration of HMI-103 nuclease-free gene editing candidate for phenylketonuria (PKU) using genome-wide assays. 2022 NPKUA Confe
- Multiple Presentations Feature HMI-103 Phase 1 Investigational Therapy for PKU, Including Genome-Wide Integration Assays to Confirm No Off-Target Editing - - New Data from GTx-mAb Program Support Potential to Target Many Complement-Related Disorders - - Presentations Feature the Discovery and Characterization of a Non-Liver-Tropic Capsid and Other Distinct Properties of Homology's Family of 15 Naturally Derived AAVHSCs - - Symposium to be Held on May 18, 2022 at 7:30 a.m. ET - BEDFORD, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that the first presentation detailing the optimization and mechanism of act
BEDFORD, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., Chief Scientific Officer, has been promoted to President of Homology. In addition to his role as CSO, Dr. Seymour will assume broader responsibilities for additional functional areas, including human resources, clinical development and operations, and commercial strategy. "Albert has fostered a culture of scientific innovation and execution that brought our first gene therapy candidate to the clinic within three years from inception, and this was followed closely by two additional trial initiations, including our first nuclease
- Formed New AAV Manufacturing and Innovation Business with Oxford Biomedica to Leverage Homology's Process Development and Manufacturing Capabilities - - Received $130 Million Non-Dilutive Capital that Significantly Extends Cash Runway - - Launched pheEDIT Gene Editing Trial for PKU and juMPStart Gene Therapy Trial for Hunter Syndrome; Program Updates Expected by Year-End - - Company Updates Guidance on pheNIX Gene Therapy Trial for PKU - BEDFORD, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2021, and highlighted recent accomplishm
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the "Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with Homology Medicines Inc. (NASDAQ:FIXX) ("Homology"), a genetic medicines company, to establish Oxford Biomedica Solutions LLC, a new US-based full scope, Adeno-Associated Virus (AAV) manufacturing and innovation business. The new Oxford Biomedica Solutions business is fully operational and offers a proprietary ‘plug and play' platform that is capable of achie
BEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today the successful closing of the deal with Oxford Biomedica plc (LSE: OXB) to establish an Adeno-Associated Virus (AAV) Manufacturing and Innovation Business. The new company, Oxford Biomedica Solutions LLC, incorporates Homology's technical and manufacturing operations, team and GMP facility with OXB's extensive know-how in viral vector manufacturing. Homology will maintain access to the capabilities that the Company built over the past four years, as well as share in potential benefits derived from future innovations as a 20% owner and preferred customer of
BEDFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences: Cowen 42nd Annual Health Care Conference: Corporate Panel Discussion – Gene Editing: March 8 at 12:50 p.m. ET Oppenheimer 32nd Annual Healthcare Conference: Fireside Chat: March 16 at 1:20 p.m. ET H.C. Wainwright Gene Therapy and Gene Editing Conference: Available on-demand March 30 at 7:00 a.m. ET The webcast presentations from the investor conferences will be accessible on Homology's website in the Investors section, and the webcast replays will be available on the website for 90 days fo